AstraZeneca (AZN) Updates FY 2018 Earnings Guidance

AstraZeneca (NYSE:AZN) issued an update on its FY 2018 earnings guidance on Thursday morning. The company provided earnings per share guidance of $3.30-3.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.68. AstraZeneca also updated its FY18 guidance to $3.30-3.50 EPS.

Shares of NYSE AZN opened at $40.97 on Friday. The stock has a market cap of $99.31 billion, a PE ratio of 9.57, a price-to-earnings-growth ratio of 2.09 and a beta of 0.57. AstraZeneca has a 1 year low of $31.99 and a 1 year high of $41.28. The company has a quick ratio of 0.54, a current ratio of 0.72 and a debt-to-equity ratio of 1.08.

AstraZeneca (NYSE:AZN) last issued its quarterly earnings data on Thursday, November 8th. The company reported $0.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.38. The firm had revenue of $5.34 billion during the quarter, compared to analysts’ expectations of $5.26 billion. AstraZeneca had a net margin of 11.98% and a return on equity of 29.89%. The business’s revenue was down 14.3% on a year-over-year basis. During the same period last year, the company earned $1.12 earnings per share. As a group, research analysts anticipate that AstraZeneca will post 1.67 EPS for the current fiscal year.

A number of research analysts have recently issued reports on AZN shares. ValuEngine upgraded shares of AstraZeneca from a hold rating to a buy rating in a report on Saturday, July 28th. Zacks Investment Research upgraded shares of AstraZeneca from a hold rating to a buy rating and set a $44.00 price objective for the company in a report on Tuesday, October 9th. Guggenheim began coverage on shares of AstraZeneca in a report on Monday, October 8th. They set a buy rating for the company. Jefferies Financial Group lowered shares of AstraZeneca from a buy rating to a hold rating in a research report on Thursday, August 16th. Finally, Wolfe Research began coverage on shares of AstraZeneca in a research report on Tuesday, October 23rd. They set an outperform rating on the stock. Four analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company has a consensus rating of Buy and an average price target of $40.34.

In other news, major shareholder Plc Astrazeneca purchased 600,000 shares of the company’s stock in a transaction that occurred on Monday, October 22nd. The shares were bought at an average cost of $5.00 per share, with a total value of $3,000,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

TRADEMARK VIOLATION WARNING: This report was published by WKRB News and is owned by of WKRB News. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.wkrb13.com/2018/11/10/astrazeneca-azn-updates-fy-2018-earnings-guidance.html.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

See Also: Growth Stocks, What They Are, What They Are Not

Earnings History and Estimates for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply